C1-esterase inhibitor deficiency results in recurrent episodes of angioedema.
INTRODUCTION
Three months before admission angioedema involving his lip occurred and was associated with non-pruritic erythematous plaques. An angiotensin converting enzyme inhibitor, taken for treatment of hypertension, was discontinued. Two months before admission facial and lip edema occurred and resolved with non-specific treatment. That episode was soon followed by hemifacial edema and transient, generalized abdominal pain. Two weeks before admission an episode of scrotal edema occurred and resolved. CT scan of the abdomen and pelvis showed no intraabdominal or pelvic adenopathy. CH50 was <10 (N=31-60), a functional assay for C1 inhibitor was 36% (N ≥68%). C1q was undetectable. A diagnosis of acquired C1esterase deficiency was made. He was begun on Rituxan, etoposide, prednisone, vincristine, doxorubicin and cyclophosphamide (R-EPOCH) for six cycles followed by two cycles of intravenous methotrexate, 8000 mg.
Post treatment, a brain MRI showed no evidence of residual disease. At ten months following his last treatment, there had been no recurrence of angioedema and no evidence of recurrent lymphoma. Following discontinuation of danazol, CH50, C1-esterase inhibitor function, and C1-esterase inhibitor protein values were normal. 
DISCUSSION
Both hereditary and acquired C1-esterase inhibitor deficiency results in episodes of angioedema, which can cause sudden airway obstruction [1] . The acquired form occurs in adults who lack a family history of angioedema. The diagnosis is confirmed by very low or undetectable C1-esterase protein, C1-esterase activity <40% and low or absent total hemolytic complement (CH50). The pathogenesis of acquired angioedema is not precisely understood, but current evidence suggests a process whereby C1-esterase inhibitor is functionally inhibited by autoantibodies [2] . Thus, acquired angioedema has been associated with autoimmune disorders in roughly 10% of cases [3] . In an additional 40% of cases, monoclonal gammopathy has been documented [4] . The remaining patients are found to have an underlying malignancy, most often an indolent non-Hodgkin B-cell lymphoma. Of the non-aggressive lymphomas, marginal zone lymphoma is most often encountered, but chronic lymphocytic leukemia and mantle cell lymphoma have also been reported [5] . Marginal zone lymphomas, both splenic and nodal forms, are associated with autoimmune phenomena [6] .
Burkitt lymphoma is a highly aggressive B-cell lymphoma.
The most common type in the United States and Western
Europe is the sporadic form, which is not associated with HIV, and is most often seen in children. In adults, however, Burkitt lymphoma represents less than 1% of all non-Hodgkin lymphomas. It is considered the fastest growing malignancy in humans [7] and frequently presents at extranodal sites [8] .
Burkitt lymphoma is considered a mature B-cell neoplasm of germinal center origin [9] and thus expresses CD10, BCL6, PAX5, CD19, and CD20. Membrane IgM is uniformly present.
Abnormalities of chromosome 8, usually a translocation with chromosome 14, allow the constitutive expression of the MYC gene, a transcriptional activator [10] , which accounts for the tumor's high replication capacity, indicated by Ki67 positivity approaching 100%.
In the case presented here, Burkitt lymphoma did not become evident until seven months following the episode of angioedema involving his upper airway. Severe leg pain and swelling was of fairly sudden onset, and progressed very rapidly. His initial evaluation at that time disclosed stage IV disease, including metastasis adjacent to the brain. A delay between onset of angioedema and discovery of a lymphoproliferative disorder is not unusual. Indeed, such a disorder may not become evident for several years following diagnosis of C1-esterase deficiency 
